Trump's executive order accelerating psychedelic drug approval raises important questions about balancing innovation with scientific rigor. While expedited pathways could bring therapeutic treatments to patients faster, experts warn that rushing regulatory processes without addressing underlying research quality concerns may compromise safety standards and clinical validity. The initiative highlights the tension between rapid access and robust evidence-based medicine in emerging pharmaceutical sectors.

Summary auto-generated by AI from the original publisher's content. Editorial standards.